Kazia Therapeutics RSI
¿Qué es el RSI de Kazia Therapeutics?
El RSI de Kazia Therapeutics Limited es 43.35
¿Cuál es la definición de RSI?
El índice de fortaleza relativa (RSI 14) es un indicador de impulso que compara la magnitud de las ganancias y pérdidas durante un período de tiempo específico para medir la velocidad y el cambio de los movimientos de precios de un valor.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI de compañías en Sector Health Care en ASX en comparadas con Kazia Therapeutics
¿Qué hace Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Empresas con rsi similar a Kazia Therapeutics
- Hindustan Fluorocarbons tiene RSI de 43.34
- Chatham Lodging Trust tiene RSI de 43.34
- A2Z Technologies Canada tiene RSI de 43.34
- Copa S.A tiene RSI de 43.34
- Pershing Square tiene RSI de 43.34
- Shivam Autotech tiene RSI de 43.34
- Kazia Therapeutics tiene RSI de 43.35
- A10 Networks Inc tiene RSI de 43.36
- Cnova N.V tiene RSI de 43.36
- Network18 Media & Investments tiene RSI de 43.36
- COMPASS Pathways plc tiene RSI de 43.36
- FG New America Acquisition tiene RSI de 43.36
- Natwest Gr.Plc Ls 1,0769 tiene RSI de 43.36